Pricing Log in Create free account

Grace Therapeutics, Inc. (GRCE) vs Veru Inc. (VERU)

Grace Therapeutics, Inc. and Veru Inc. are both Biotechnology companies. Grace Therapeutics, Inc. and Veru Inc. are of similar size ($41.6M and $41.0M). Grace Therapeutics, Inc. grew revenue faster over the last twelve months: 1,286.8% against 52.7%. Across the 14 metrics below, Grace Therapeutics, Inc. leads on 7 and Veru Inc. on 7.

Valuation

Metric GRCE VERU Biotechnology median
P/E n/m n/m 8.50
P/S 163.45 2.13 9.71
P/B 0.68 1.87 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 108.68 1.22 9.21
Earnings yield (62.43%) (25.24%) (33.15%)
Free cash flow yield (31.27%) (49.13%) (25.50%)

Profitability

Metric GRCE VERU Biotechnology median
Gross margin 0.00% 32.44% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (36.19%) (62.25%) (56.36%)
Return on assets (33.74%) (42.29%) (48.04%)
Return on invested capital (43.36%) (464.03%) 0.00%

Growth

Metric GRCE VERU Biotechnology median
Revenue growth (TTM) 1,286.81% 52.69% 6.02%
EPS growth (last fiscal year) 40.51% 44.64% 30.26%
Revenue growth, 5-year CAGR (22.91%) (11.89%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GRCE VERU Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.47 4.42 4.72
Net debt to EBITDA 1.53 0.74 0.96

Dividend

Metric GRCE VERU Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GRCE VERU Biotechnology median
Market cap 41.02m 41.61m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack